Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anthraquinone SCHEMBL27983859 | 0.85 | SLC7A5 (0.60) | SLC7A5LMNAMAPK1ALDH1A1MEN1 | |
| Anthraquinone SCHEMBL3654040 | 0.85 | SLC7A5 (0.60) | SLC7A5LMNAMAPK1ALDH1A1MEN1 | |
| Isatin SCHEMBL3360463 | 0.83 | MAOA (0.59) | SLC7A5CASP7CASP3CASP2CASP6 | |
| Phthalic Anhydride SCHEMBL8525072 | 0.81 | SLC7A5 (0.54) | SLC7A5HSD17B10LMNASMN1; SMN2ALDH1A1 | |
| Saccharin SCHEMBL27749779 | 0.79 | CA12 (0.63) | SLC7A5CASP7HSD17B10LMNAALDH1A1 | |
| Saccharin SCHEMBL28161546 | 0.79 | CA12 (0.63) | SLC7A5CASP7HSD17B10LMNAALDH1A1 | |
| Valine SCHEMBL10559201 | 0.78 | SLC7A5 (0.50) | SLC7A5CASP3HSD17B10LMNAMAPK1 | |
| Biphenyl SCHEMBL2494151 | 0.77 | SLC7A5 (0.65) | SLC7A5SMN1; SMN2MAPTSLC1A2SLC1A3 | |
| Biphenyl SCHEMBL27824248 | 0.77 | SLC7A5 (0.65) | SLC7A5SMN1; SMN2MAPTSLC1A2SLC1A3 | |
| Phthalimide SCHEMBL29036210 | 0.77 | PTGS2 (0.55) | GSK3BCASP7CASP3CASP2CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2354136-B1 | NOVEL DOPAMINE D3 RECEPTOR LIGANDS AND PREPARATION AND MEDICAL USES OF THE SAME | INST PHARM & TOXICOLOGY AMMS (CN) | 2016-02-24 | — | — | EP | disclosed |
| US-9227944-B2 | Dopamine D3 receptor ligands and preparation and medical uses of the same | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY SCIENCE P.L.A. CHINA (CN) | 2016-01-05 | — | — | US | disclosed |
| US-20140329831-A1 | NOVEL DOPAMINE D3 RECEPTOR LIGANDS AND PREPARATION AND MEDICAL USES OF THE SAME | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCE P.L.A. CHINA (CN) | 2014-11-06 | — | — | US | disclosed |
| US-8829001-B2 | Dopamine D3 receptor ligands and preparation and medical uses of the same | The Institute of Pharmacology and Toxicology Academy of Military Medical Science P.L.A. China (CN) | 2014-09-09 | — | — | US | disclosed |
| US-20110319423-A1 | NOVEL DOPAMINE D3 RECEPTOR LIGANDS AND PREPARATION AND MEDICAL USES OF THE SAME | Institute of Pharmacology and Toxicology Academy of Military Medical Science, P.L.A (CN) | 2011-12-29 | — | — | US | disclosed |
| CN-102264733-A | novel dopamine D3 receptor ligand, preparation method and medical application thereof | — | 2011-11-30 | — | — | CN | disclosed |
| EP-2354136-A1 | NOVEL DOPAMINE D3 RECEPTOR LIGANDS, THE PREPARATION AND USE THEREOF | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China (CN) | 2011-08-10 | — | — | EP | disclosed |
| EP-0207684-B1 | 7-Oxabicycloheptane substituted diamide and its congener prostaglandin analogs | SQUIBB & SONS INC (US) | 1994-11-23 | — | — | EP | disclosed |
| US-4738978-A | ANTICOAGULANT, ANTIALLERGENS | E. R. SQUIBB & SONS, INC. (US) | 1988-04-19 | — | — | US | disclosed |
| US-4735962-A | ANTICOAGULANTS, BRONCHODILATORS | E. R. SQUIBB & SONS, INC. (US) | 1988-04-05 | — | — | US | disclosed |
| US-4647573-A | 7-oxabicycloheptane substituted thioamide-amide prostaglandin analogs | E. R. SQUIBB & SONS, INC. (US) | 1987-03-03 | — | — | US | disclosed |
| EP-0210664-A2 | 7-oxabicycloheptane substituted diacid diamide prostaglandin analogs | E.R. Squibb & Sons, Inc. (US) | 1987-02-04 | — | — | EP | disclosed |
| US-4639461-A | INHIBITORS OF ACTION OF ARACHIDONIC ACID | E. R. SQUIBB & SONS, INC. (US) | 1987-01-27 | — | — | US | disclosed |
| US-4638012-A | 7-oxabicycloheptane α-substituted ketone prostaglandin analogs useful in the treatment of thrombotic disease | E. R. SQUIBB & SONS, INC. (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0207684-A2 | 7-Oxabicycloheptane substituted diamide and its congener prostaglandin analogs | E.R. Squibb & Sons, Inc. (US) | 1987-01-07 | — | — | EP | disclosed |
| US-4632931-A | ANTICOAGULANTS, BRONCHODILATOR AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1986-12-30 | — | — | US | disclosed |
| EP-0150709-A2 | 7-oxabicycloheptane prostaglandin analogs | E.R. Squibb & Sons, Inc. (US) | 1985-08-07 | — | — | EP | disclosed |
| EP-0150710-A2 | 7-Oxabicycloheptane prostaglandin analogs | E.R. Squibb & Sons, Inc. (US) | 1985-08-07 | — | — | EP | disclosed |
| US-4533673-A | 7-Oxabicycloheptane substituted enaminone prostaglandin analogs and their use in treatment of thrombolytic disease | E. R. SQUIBB & SONS, INC. (US) | 1985-08-06 | — | — | US | disclosed |
| US-4526901-A | 7-Oxabicycloheptane substituted oxamide prostaglandin analogs and their use in treating thrombolytic disease | E. R. SQUIBB & SONS, INC. (US) | 1985-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319423-A1 | NOVEL DOPAMINE D3 RECEPTOR LIGANDS AND PREPARATION AND MEDICAL USES OF THE SAME | DRD3, DRD2, SLC6A3 | GSK3B 1774/4885SLC7A5 2305/4885CASP7 2829/4885 |
| US-20140329831-A1 | NOVEL DOPAMINE D3 RECEPTOR LIGANDS AND PREPARATION AND MEDICAL USES OF THE SAME | DRD3, DRD2, SLC6A3 | GSK3B 1774/4885SLC7A5 2305/4885CASP7 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.